Table 4.
Objective clinical efficacy (ITT population) at 48–72 h after start of treatment
| Delafloxacin | Linezolid | Vancomycin | |
|---|---|---|---|
| Outcome/measurement technique | |||
| erythema/digital measurement | |||
| cessation of spread,a n/N (%) | 61/78 (78.2) | 56/75 (74.7) | 69/95 (72.6) |
| 20% reduction, n/N (%) | 58/78 (74.4) | 55/75 (73.3) | 65/95 (68.4) |
| percentage change in area at follow-up, mean (SD) | −96.4 (13.96) | −87.7 (39.22) | −84.5 (35.73)b |
| Induration/digital measurement | |||
| cessation of spread,a n/N (%) | 54/78 (69.2) | 47/75 (62.7) | 72/95 (75.8) |
| 20% reduction, n/N (%) | 44/78 (56.4) | 40/75 (53.3) | 66/95 (69.5) |
| percentage change in area at follow-up, mean (SD) | −73.5 (48.56) | −77.1 (47.02) | −84.8 (30.05) |
| Body temperature (°C)c | |||
| change from baseline to follow-up, mean (SD) | −0.2 (0.53) | −0.2 (0.59) | −0.2 (0.76) |
| Serum CRP (mg/L)d | |||
| change from baseline to follow-up, mean (SD) | −37.4 (64.90) | −38.1 (54.51) | −43.2 (64.90) |
| Serum IL-6 (ng/L)e | |||
| change from baseline to follow-up, mean (SD) | −7.9 (15.84) | −8.7 (19.11) | −9.7 (19.33)b |
aProportion of patients in whom erythema or induration had stopped expanding within 48–72 h, accompanied by resolution or continuing absence of fever.
bP < 0.05 versus delafloxacin, Cochran–Mantel–Haenszel test.
cn = 78 delafloxacin, 73 linezolid and 96 vancomycin.
dn = 71 delafloxacin, 69 linezolid and 92 vancomycin.
en = 71 delafloxacin, 68 linezolid and 93 vancomycin.